The Biostatistics Shared Resource (BSR) of the Mayo Clinic Cancer Center (MCCC) has provided expert statistical collaboration with MCCC investigators for over 35 years. The purpose is to provide statistical and biomathematical collaboration for the development and conduct of peer-reviewed cancer research generated by MCCC investigators. Research encompasses basic science, clinical trials, epidemiologic research, and other translational and educational research. The primary usage of CCSG funds is to support statistical and biomathematical collaboration on pilot projects, for assistance to investigators in developing approved research projects not otherwise funded but leading towards external funding, and to support unanticipated needs for statistical collaboration on MCCC approved projects. Over its history the BSR has undergone a natural and deliberate evolution and expansion, spurred by the expanding research activities of the MCCC. In the current grant period the BSR has successfully and strategically expanded in two primary areas: high dimensional genomic and proteomic data analysis (4 new faculty with this expertise), and to all 3 MCCC campuses. BSR faculty are physically located on all 3 MCCC campuses, and the entire resource communicates regularly and effectively through multiple mechanisms to ensure coordinated collaboration. The BSR has multiple focus areas (teams) tied together into a well-organized, efficient core. These are: (I) a Clinical Trials team responsible for cancer clinical trials, associated translational research, interventional psychosocial research, and patient and public education research projects, (II) a Population Science team responsible for providing statistical collaboration and data management support for cancer observational studies, including genetic and molecular epidemiology, (III) a Quality of Life team responsible for providing general and specific collaboration, measurement tools, and analysis for MCCC investigators investigating the impact of clinical and psychosocial interventions on cancer patients, families, caregivers, and others, and (IV) a Biomathematics team that provides collaborative expertise in the mathematical aspects of imaging, data processing and analysis, mathematical modeling of diease processes, and general mathematical or algorithmic issues. The BSR provides statistical and biomathematical collaboration to MCCC investigators across all three MCCC campuses. The resource has been remarkably productive, with 528 peer reviewed publications in the current grant period, and has collaborated on 104 NIH or NIH equivalent grants in the current grant period.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-38
Application #
8382249
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-03-01
Budget End
2013-02-28
Support Year
38
Fiscal Year
2012
Total Cost
$429,436
Indirect Cost
$69,531
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Paulus, A; Akhtar, S; Yousaf, H et al. (2017) Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. Blood Cancer J 7:e565
Li, Mulin Jun; Li, Miaoxin; Liu, Zipeng et al. (2017) cepip: context-dependent epigenomic weighting for prioritization of regulatory variants and disease-associated genes. Genome Biol 18:52
Finnes, Heidi D; Chaffee, Kari G; Call, Timothy G et al. (2017) Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice. Leuk Lymphoma 58:1376-1383
Patnaik, Mrinal M; Barraco, Daniela; Lasho, Terra L et al. (2017) Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. Am J Hematol 92:542-548
Pathangey, Latha B; McCurry, Dustin B; Gendler, Sandra J et al. (2017) Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens. Oncotarget 8:10785-10808
Russell, Stephen J; Peng, Kah-Whye (2017) Oncolytic Virotherapy: A Contest between Apples and Oranges. Mol Ther 25:1107-1116
Ertz-Archambault, Natalie; Kosiorek, Heidi; Taylor, Gretchen E et al. (2017) Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia. JAMA Oncol 3:936-943
Peacock, Justin G; Harmsen, William S; Link, Michael J et al. (2017) Risk of Delayed Lymph Node Metastasis in Clinically N0 Esthesioneuroblastoma. J Neurol Surg B Skull Base 78:68-74
Miyoshi, Jinsei; Toden, Shusuke; Yoshida, Kazuhiro et al. (2017) MiR-139-5p as a novel serum biomarker for recurrence and metastasis in colorectal cancer. Sci Rep 7:43393
Wu, Y; Vadgama, J V (2017) Androgen Receptor as a Potential Target for Treatment of Breast Cancer. Int J Cancer Res Mol Mech 3:

Showing the most recent 10 out of 1086 publications